Table 1.
Demographics and some other parameters in the different groups
| Placebo (n = 24) |
Prostacyclin (n = 21) |
p | |
|---|---|---|---|
| Women (n) | 6 | 9 | 0.2049, χ2 |
| Men (n) | 18 | 12 | |
| Age (years, mean ± SEM) | 34.0 ± 2.4 | 37.1 ± 3.8 | 0.4846, t test |
| GCS (median, min–max) | 6 (3–8) | 5 (3–8) | 0.2220, Wilcoxon rank-sum |
| ISS (mean ± SEM) | 27.7 ± 2.1 | 29.7 ± 2.1 | 0.5230, t test |
| MAP (mmHg, mean ± SEM) | 80.1 ± 1.5 | 82.2 ± 1.1 | 0.3689, t test |
| ICP (mmHg, mean ± SEM) | 18.5 ± 2.6 | 16.3 ± 0.9 | 0.4341, t test |
| CPP (mmHg, mean ± SEM) | 62.1 ± 2.5 | 63.9 ± 3.0 | 0.6479, t test |
| CT scan time from injury (h ± sem) | 3.2 ± 0.7 | 2.8 ± 0.6 | 0.7257, t test |
| Rotterdam score (median, min–max) | |||
| Initial | 3 (1–5) | 3 (2–4) | 0.9519, Wilcoxon rank-sum |
| At 24 h after trauma | 2.4 (1–5) | 3 (2–4) | 0.6062 |
| Hemicraniectomy (n) | 9/24 | 8/21 | 0.9672, χ2 |
| MDL (mm, mean ± SEM) | 13.8 ± 2.6 | 16.3 ± 3.2 | 0.5559, t test |
| MDD (n) | 4/24 | 4/21 | 0.8349, χ2 |
| Lactate/pyruvate ratio | 46.6 ± 7.4 | 43.5 ± 4.3 | 0.8556, Wilcoxon rank-sum |
| GOSE (median) | 4.5 (1–8) | 5 (1–8) | 0.7895, Wilcoxon rank-sum |
| Mortality (%) | 16.7 | 14.3 | 0.8257, χ2 |
The statistical comparisons are between the two groups
CPP cerebral perfusion pressure, CT computed tomography, GCS Glasgow coma score, GOSE Glasgow outcome scale extended, ICP intracranial pressure, ISS injury severity score, MAP mean arterial blood pressure, MDD microdialysis in diffuse injury, MDL microdialysis probe distance to lesion